UFP Technologies heads into its Q1 2026 report on May 5 as one of the more heavily shorted names in the health care supplies space — and shorts have been rebuilding quietly over recent weeks.
Short sellers have been adding exposure rather than retreating. SI as a percent of free float is running at 15.6%, up roughly 1.9 percentage points from late March levels, with the share count edging higher each session through the final week of April. The ORTEX short score is 70.7 — placing shorts in the top 5th percentile for intensity among US stocks — while days to cover has stretched to 9.7, meaning bears face nearly two weeks of average volume to unwind. Despite that conviction, borrow conditions remain relaxed: cost to borrow is below 0.6%, and borrow availability is comfortably above 100%, suggesting shorts can still access the stock without meaningful friction. The stock itself has given back 2.4% on the week heading into the print, and is down 12.6% year-to-date.
Options positioning has turned less defensive than it has been. The put/call ratio is running at 1.41 — still bearish in absolute terms, but well below its 20-day average of 1.77. That's nearly a full standard deviation below the recent norm, suggesting traders have been reducing downside hedges rather than adding them. The contrast with the elevated short interest is notable: shorts are firm, but options players are not piling on fresh protection.
The analyst picture is stale. The most recent target-price action on file dates to August 2025, when Lake Street raised its target to $289 while maintaining a Buy — a level the stock has since traded through and given back. With the consensus price target sitting at $324.50 against a current price of $192.55, the gap looks substantial, though some of that divergence likely reflects the YTD decline rather than fresh analyst conviction. The most recent formal coverage action was Raymond James initiating at Market Perform in March 2025, which tempers the bullish read. On the institutional side, the top holder changes are modest — Wasatch and Congress both added around 40,000 shares in Q1, while Thrivent built a more significant 132,882-share position as recently as March, suggesting some active managers were buying into the weakness.
A cluster of five insiders — including the Chairman and CEO and the CFO — sold a combined $3.25 million in stock on March 2, at prices around $204, above where the stock trades today. The February earnings print produced only a fractional move, but the prior report in November 2025 triggered a 10.4% single-day drop and a 15.2% five-day loss. Today's print will test whether the business can reassure a market that is structurally short the stock, or whether the heavy short base reflects well-founded concerns about the trajectory of earnings.
See the live data behind this article on ORTEX.
Open UFPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
